Medication adherence and persistence in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and qualitative update.

ADHD medication Adherence Adolescents Children Persistence Systematic literature review

Journal

European child & adolescent psychiatry
ISSN: 1435-165X
Titre abrégé: Eur Child Adolesc Psychiatry
Pays: Germany
ID NLM: 9212296

Informations de publication

Date de publication:
06 Aug 2024
Historique:
received: 23 02 2024
accepted: 15 07 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: aheadofprint

Résumé

Low medication-adherence and persistence may reduce the effectiveness of ADHD-medication. This preregistered systematic review (PROSPERO CRD42020218654) on medication-adherence and persistence in children and adolescents with ADHD focuses on clinically relevant questions and extends previous reviews by including additional studies. We included a total of n = 66 studies. There was a lack of consistency in the measurement of adherence/persistence between studies. Pooling the medication possession ratios (MPR) and using the most common adherence definition (MPR ≥ 80%) indicated that only 22.9% of participants had good adherence at 12-month follow-up. Treatment persistence on medication measured by treatment duration during a 12-month follow-up averaged 170 days (5.6 months). Our findings indicate that medication-adherence and persistence among youth with ADHD are generally poor and have not changed in recent years. Clinicians need to be aware that various factors may contribute to poor adherence/persistence and that long-acting stimulants and psychoeducational programs may help to improve adherence/persistence. However, the evidence to whether better adherence/persistence contributes to better long-term outcomes is limited and requires further research.

Identifiants

DOI: 10.1007/s00787-024-02538-z PMID: 39105823
pubmed: 39105823
doi: 10.1007/s00787-024-02538-z
pii: 10.1007/s00787-024-02538-z
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Dieter Baeyens (D)
Tobias Banaschewski (T)
Sven Bölte (S)
Daniel Brandeis (D)
Jan K Buitelaar (JK)
Sara Carucci (S)
David Coghill (D)
Samuele Cortese (S)
David Daley (D)
Manfred Döpfner (M)
Maite Ferrin (M)
Cedric Galera (C)
Chris Hollis (C)
Holtmann Martin (H)
Peter Nagy (P)
Diane Purper-Ouakil (D)
J Antoni Ramos-Quiroga (JA)
Marcel Romanos (M)
Paramala J Santosh (PJ)
Emily Simonoff (E)
Edmund Sonuga-Barke (E)
Cesar A Soutullo (CA)
Hans-Christoph Steinhausen (HC)
Anita Thapar (A)
Barbara J Van den Hoofdakker (BJ)
Saskia Van der Oord (S)
Ian C K Wong (ICK)

Informations de copyright

© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Polanczyk GV et al (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43(2):434–442
pubmed: 24464188 pmcid: 4817588 doi: 10.1093/ije/dyt261
Biederman J, Mick E, Faraone SV (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 157(5):816–818
pubmed: 10784477 doi: 10.1176/appi.ajp.157.5.816
Barkley RA, Fischer M (2019) Hyperactive child syndrome and estimated life expectancy at young adult follow-up: the role of ADHD persistence and other potential predictors. J Atten Disord 23(9):907–923
pubmed: 30526189 doi: 10.1177/1087054718816164
Pelham WE et al (2020) The long-term financial outcome of children diagnosed with ADHD. J Consult Clin Psychol 88(2):160–171
pubmed: 31789549 doi: 10.1037/ccp0000461
Faraone SV et al (2021) The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev 128:789–818
pubmed: 33549739 pmcid: 8328933 doi: 10.1016/j.neubiorev.2021.01.022
Kittel-Schneider S et al (2022) Non-mental diseases associated with ADHD across the lifespan: fidgety Philipp and Pippi longstocking at risk of multimorbidity? Neurosci Biobehav Rev 132:1157–1180
pubmed: 34757108 doi: 10.1016/j.neubiorev.2021.10.035
Dalsgaard S et al (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385(9983):2190–2196
pubmed: 25726514 doi: 10.1016/S0140-6736(14)61684-6
NICE. 2018; Available from: https://www.nice.org.uk/guidance/ng87 . Accessed 26 July 2023
CADDRA. 2018; Available from: https://www.caddra.ca/download-guidelines/ Accessed 26 July 2023
Boland H et al (2020) A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 123:21–30
pubmed: 32014701 doi: 10.1016/j.jpsychires.2020.01.006
Cortese S et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727–738
pubmed: 30097390 pmcid: 6109107 doi: 10.1016/S2215-0366(18)30269-4
Mechler K et al (2022) Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther 230:107940
pubmed: 34174276 doi: 10.1016/j.pharmthera.2021.107940
Coghill D (2019) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (For). J Am Acad Child Adolesc Psychiatry 58(10):938–939
pubmed: 31515164 doi: 10.1016/j.jaac.2019.07.002
Swanson JM (2019) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (Against). J Am Acad Child Adolesc Psychiatry 58(10):936–938
pubmed: 31515165 doi: 10.1016/j.jaac.2019.07.001
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497
pubmed: 16079372 doi: 10.1056/NEJMra050100
Cramer JA et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47
pubmed: 18237359 doi: 10.1111/j.1524-4733.2007.00213.x
Gajria K et al (2014) Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder—a systematic literature review. Neuropsychiatr Dis Treat 10:1543–1569
pubmed: 25187718 pmcid: 4149449
Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22(3):787–797
pubmed: 1357703 doi: 10.1017/S0033291700038228
Vrijens B et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705
pubmed: 22486599 pmcid: 3403197 doi: 10.1111/j.1365-2125.2012.04167.x
Perwien A et al (2004) Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 10(2):122–129
pubmed: 15032561
Ahmed R, Aslani P (2013) Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res 13(6):791–815
pubmed: 24219052 doi: 10.1586/14737167.2013.841544
Charach A, Fernandez R (2013) Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep 15(7):371
pubmed: 23712722 pmcid: 3718998 doi: 10.1007/s11920-013-0371-6
Adler LD, Nierenberg AA (2010) Review of medication adherence in children and adults with ADHD. Postgrad Med 122(1):184–191
pubmed: 20107302 doi: 10.3810/pgm.2010.01.2112
Atzori P et al (2009) Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 19(6):673–681
pubmed: 20035585 doi: 10.1089/cap.2008.0146
Corkum P, Rimer P, Schachar R (1999) Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatry 44(10):1043–1048
pubmed: 10637684 doi: 10.1177/070674379904401011
Yang J et al (2012) Adherence with electronic monitoring and symptoms in children with attention deficit hyperactivity disorder. Psychiatry Investig 9(3):263–268
pubmed: 22993526 pmcid: 3440476 doi: 10.4306/pi.2012.9.3.263
Weisman O et al (2018) Testing the efficacy of a smartphone application in improving medication adherence, among children with ADHD. Isr J Psychiatry 55(2):59–63
pubmed: 30368489
Charach A et al (2008) Documenting adherence to psychostimulants in children with ADHD. J Can Acad Child Adolesc Psychiatry 17(3):131–136
pubmed: 18769643 pmcid: 2527765
Emilsson M et al (2017) Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder. Eur Child Adolesc Psychiatry 26(5):559–571
pubmed: 27848023 doi: 10.1007/s00787-016-0919-1
Hodgkins P, Sasané R, Meijer WM (2011) Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 33(2):188–203
pubmed: 21497704 doi: 10.1016/j.clinthera.2011.03.001
Christensen L et al (2010) Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 26(4):977–989
pubmed: 20178404 doi: 10.1185/03007991003673617
Marcus SC, Durkin M (2011) Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50(5):480–489
pubmed: 21515197 doi: 10.1016/j.jaac.2011.02.007
Hébert J et al (2013) Adherence to psychostimulant medication in children with attention-deficit/hyperactivity disorder: the role of attitudes. J Can Acad Child Adolesc Psychiatry 22(4):317–323
pubmed: 24223052 pmcid: 3825473
el Ibrahim SR (2002) Rates of adherence to pharmacological treatment among children and adolescents with attention deficit hyperactivity disorder. Hum Psychopharmacol 17(5):225–231
pubmed: 12404679 doi: 10.1002/hup.406
Efron D et al (2020) Patterns of long-term ADHD medication use in Australian children. Arch Dis Child 105(6):593–597
pubmed: 31937570 doi: 10.1136/archdischild-2019-317997
Lawson KA et al (2012) Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther 34(4):944-956.e4
pubmed: 22444786 doi: 10.1016/j.clinthera.2012.02.021
Lachaine J et al (2012) Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med 124(3):139–148
pubmed: 22691908 doi: 10.3810/pgm.2012.05.2557
Antony A (2016) Study of factors influencing treatment adherence in childhood attention deficit hyperactivity disorder in a tertiary healthcare facility. Indian J Psychol Med 38(1):20–24
pubmed: 27011397 pmcid: 4782439 doi: 10.4103/0253-7176.175094
Pappadopulos E et al (2009) Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 48(5):501–510
pubmed: 19307987 doi: 10.1097/CHI.0b013e31819c23ed
Hong M et al (2014) A 36 month naturalistic retrospective study of clinic-treated youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 24(6):341–346
pubmed: 24955936 doi: 10.1089/cap.2013.0090
Sitholey P, Agarwal V, Chamoli S (2011) A preliminary study of factors affecting adherence to medication in clinic children with attention-deficit/hyperactivity disorder. Indian J Psychiatry 53(1):41–44
pubmed: 21431007 pmcid: 3056187 doi: 10.4103/0019-5545.75561
Hong M et al (2016) Naturalistic pharmacotherapy compliance among pediatric patients with attention deficit/hyperactivity disorder: a study based on three-year nationwide data. J Korean Med Sci 31(4):611–616
pubmed: 27051247 pmcid: 4810346 doi: 10.3346/jkms.2016.31.4.611
Hodgkins P et al (2013) Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr 172(7):895–906
pubmed: 23440479 pmcid: 3701791 doi: 10.1007/s00431-013-1969-8
Bhang SY et al (2017) Factors that affect the adherence to ADHD medications during a treatment continuation period in children and adolescents: a nationwide retrospective cohort study using korean health insurance data from 2007 to 2011. Psychiatry Investig 14(2):158–165
pubmed: 28326113 pmcid: 5355013 doi: 10.4306/pi.2017.14.2.158
Kiliç BG et al (2007) Sociodemographic and clinical factors associated with compliance to methylphenidate treatment in children with attention deficit hyperactivity disorder. Turk Psikiyatri Derg 18(3):207–213
pubmed: 17853975
Thiruchelvam D, Charach A, Schachar RJ (2001) Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 40(8):922–928
pubmed: 11501692 doi: 10.1097/00004583-200108000-00014
Cummings JR et al (2017) Racial and ethnic differences in ADHD treatment quality among medicaid-enrolled youth. Pediatrics. https://doi.org/10.1542/peds.2016-2444
doi: 10.1542/peds.2016-2444 pubmed: 28562259
Bai GN et al (2015) Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: improvement of medication adherence and symptoms. Neuropsychiatr Dis Treat 11:2721–2735
pubmed: 26604761 pmcid: 4655671
Ji X et al (2018) Racial-ethnic differences in patterns of discontinuous medication treatment among medicaid-insured youths with ADHD. Psychiatr Serv 69(3):322–331
pubmed: 29191137 doi: 10.1176/appi.ps.201600469
Wong IC et al (2009) Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study. Health Technol Assess 13(50):1 iii-iv-120 ix-xi
pubmed: 19883527
Bahmanyar S et al (2013) Pharmacological treatment and demographic characteristics of pediatric patients with attention deficit hyperactivity disorder Sweden. Eur Neuropsychopharmacol 23(12):1732–1738
pubmed: 23953271 doi: 10.1016/j.euroneuro.2013.07.009
McCarthy S et al (2009) Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 194(3):273–277
pubmed: 19252159 doi: 10.1192/bjp.bp.107.045245
MTA_Cooperative_Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 56(12): 1073–86.
MTA_Cooperative_Group (1999) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 56(12): p. 1088–96.
Fried R et al (2020) An innovative SMS intervention to improve adherence to stimulants in children with ADHD: preliminary findings. J Psychopharmacol 34(8):883–890
pubmed: 32077768 doi: 10.1177/0269881120908014
Biederman J et al (2019) Evidence of low adherence to stimulant medication among children and youths with ADHD: an electronic health records study. Psychiatr Serv 70(10):874–880
pubmed: 31242830 doi: 10.1176/appi.ps.201800515
Gau SS et al (2008) National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69(1):131–140
pubmed: 18312048 doi: 10.4088/JCP.v69n0118
Palli SR et al (2012) Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 22(2):139–148
pubmed: 22364400 doi: 10.1089/cap.2011.0028
Marcus SC et al (2005) Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 159(6):572–578
pubmed: 15939858 doi: 10.1001/archpedi.159.6.572
Chou WJ et al (2009) Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 63(2):167–175
pubmed: 19335386 doi: 10.1111/j.1440-1819.2009.01937.x
Rothenberger A et al (2011) An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Eur Child Adolesc Psychiatry 20(Suppl 2):S257–S265
pubmed: 21901416 doi: 10.1007/s00787-011-0203-3
Olfson M, Marcus S, Wan G (2009) Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry 48(1):51–59
pubmed: 19218896 doi: 10.1097/CHI.0b013e31818b1c8f
Meyers J et al (2017) The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res 6(2):109–125
pubmed: 28118752 doi: 10.2217/cer-2016-0039
Lambert MC et al (2015) A survival analysis of psychostimulant prescriptions in New South Wales from 1990 to 2010. J Child Adolesc Psychopharmacol 25(6):475–481
pubmed: 26218772 doi: 10.1089/cap.2014.0151
Gau SS et al (2006) Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 16(3):286–297
pubmed: 16768636 doi: 10.1089/cap.2006.16.286
Faraone SV, Biederman J, Zimmerman B (2007) An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord 11(2):157–166
pubmed: 17494833 doi: 10.1177/1087054706295663
Braun S et al (2013) Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany. Clin Ther 35(5):673–685
pubmed: 23587606 doi: 10.1016/j.clinthera.2013.03.017
Tuncturk M et al (2023) Investigating the effects of age, IQ, dosing, and anthropometric measures on the treatment persistence in long-term methylphenidate use. Nord J Psychiatry 77(4):345–351
pubmed: 36001399 doi: 10.1080/08039488.2022.2112284
Molife C et al (2018) Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine. Curr Med Res Opin 34(4):619–632
pubmed: 29298540 doi: 10.1080/03007995.2017.1421918
Su Y et al (2016) Osmotic release oral system methylphenidate versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in chinese youth: 8-week comparative efficacy and 1-year follow-up. J Child Adolesc Psychopharmacol 26(4):362–371
pubmed: 26779845 doi: 10.1089/cap.2015.0031
Wehmeier PM, Dittmann RW, Banaschewski T (2015) Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study. Atten Defic Hyperact Disord 7(2):165–174
pubmed: 25416667 doi: 10.1007/s12402-014-0156-8
Raman SR et al (2015) An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom. Psychiatr Serv 66(6):617–624
pubmed: 25726974 doi: 10.1176/appi.ps.201300148
Greven P et al (2017) Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany. Eur J Health Econ 18(7):893–904
pubmed: 27817164 doi: 10.1007/s10198-016-0836-8
Brinkman WB et al (2016) Relationship between attention-deficit/hyperactivity disorder care and medication continuity. J Am Acad Child Adolesc Psychiatry 55(4):289–294
pubmed: 27015719 pmcid: 4808569 doi: 10.1016/j.jaac.2016.02.001
Johnston C, Fine S (1993) Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 18(6):717–730
pubmed: 8138866 doi: 10.1093/jpepsy/18.6.717
Tzang RF et al (2012) Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Psychiatry Clin Neurosci 66(1):53–63
pubmed: 22250610 doi: 10.1111/j.1440-1819.2011.02289.x
Bruno C et al (2023) Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: a population-based study among Australian children and adults (2013–2020). Aust N Z J Psychiatry 57(5):675–685
pubmed: 35999695 doi: 10.1177/00048674221114782
Miller AR, Lalonde CE, McGrail KM (2004) Children’s persistence with methylphenidate therapy: a population-based study. Can J Psychiatry 49(11):761–768
pubmed: 15633854 doi: 10.1177/070674370404901107
Niemeyer L et al (2018) “When I stop my medication, everything goes wrong”: content analysis of interviews with adolescent patients treated with psychotropic medication. J Child Adolesc Psychopharmacol 28(9):655–662
pubmed: 30148662 doi: 10.1089/cap.2018.0072
Kamimura-Nishimura KI, Brinkman WB, Froehlich TE (2019) Strategies for improving ADHD medication adherence. Curr Psychiatr 18(8):25–38
pubmed: 33867872 pmcid: 8049396
Khan MU, Aslani P (2019) A review of factors influencing the three phases of medication adherence in people with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 29(6):398–418
pubmed: 31120328 doi: 10.1089/cap.2018.0153
Charach A, Ickowicz A, Schachar R (2004) Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43(5):559–567
pubmed: 15100562 doi: 10.1097/00004583-200405000-00009
Leslie LK et al (2007) Investigating ADHD treatment trajectories: listening to families’ stories about medication use. J Dev Behav Pediatr 28(3):179–188
pubmed: 17565284 doi: 10.1097/DBP.0b013e3180324d9a
Chen CY, Gerhard T, Winterstein AG (2009) Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(2):187–195
pubmed: 19364296 doi: 10.1089/cap.2008.096
Chen CY et al (2011) Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21(3):265–273
pubmed: 21663429 doi: 10.1089/cap.2010.0107
Baweja R, Soutullo CA, Waxmonsky JG (2021) Review of barriers and interventions to promote treatment engagement for pediatric attention deficit hyperactivity disorder care. World J Psychiatry 11(12):1206–1227
pubmed: 35070771 pmcid: 8717033 doi: 10.5498/wjp.v11.i12.1206
Swanson JM et al (2017) Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression. J Child Psychol Psychiatry 58(6):663–678
pubmed: 28295312 pmcid: 6168061 doi: 10.1111/jcpp.12684
Sherman M, Hertzig M (1991) Prescribing practices of ritalin: the Suffolk County, New York study. Ritalin: Theory and patient management. p. 187–193.
Biederman J et al (2010) A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 157(4):635–40 640.e1
pubmed: 20605163 pmcid: 2943875 doi: 10.1016/j.jpeds.2010.04.025
Pottegård A et al (2012) The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol 68(10):1443–1450
pubmed: 22434389 doi: 10.1007/s00228-012-1265-y
van den Ban E et al (2010) Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. Atten Defic Hyperact Disord 2(4):213–220
pubmed: 21258431 pmcid: 3000908 doi: 10.1007/s12402-010-0044-9
Zetterqvist J et al (2013) Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatr Scand 128(1):70–77
pubmed: 22943458 doi: 10.1111/acps.12004
Jensen PS et al (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46(8):989–1002
pubmed: 17667478 doi: 10.1097/CHI.0b013e3180686d48
Chacko A et al (2010) Improving medication adherence in chronic pediatric health conditions: a focus on ADHD in youth. Curr Pharm Des 16(22):2416–2423
pubmed: 20513228 doi: 10.2174/138161210791959908
Zheng X et al (2020) Parent and teacher training increases medication adherence for primary school children with attention-deficit/hyperactivity disorder. Front Pediatr 8:486353
pubmed: 33240827 pmcid: 7680838 doi: 10.3389/fped.2020.486353
Ferrin M et al (2020) A randomized controlled trial evaluating the efficacy of a psychoeducation program for families of children and adolescents with ADHD in the United Kingdom: results after a 6-month follow-up. J Atten Disord 24(5):768–779
pubmed: 26838557 doi: 10.1177/1087054715626509
Ferrin M et al (2014) Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: immediate and long-term effects using a blind randomized controlled trial. Eur Child Adolesc Psychiatry 23(8):637–647
pubmed: 24292412 doi: 10.1007/s00787-013-0494-7
Montoya A, Colom F, Ferrin M (2011) Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review. Eur Psychiatry 26(3):166–175
pubmed: 21292454 doi: 10.1016/j.eurpsy.2010.10.005
van Langen MJM et al (2022) Lost in explanation: internal conflicts in the discourse of ADHD psychoeducation. BMC Psychiatry 22(1):690
pubmed: 36348316 pmcid: 9644452 doi: 10.1186/s12888-022-04327-x
Colom F, Vieta E (2006) Psychoeducation manual for bipolar disorder. Cambridge University Press, Cambridge
doi: 10.1017/CBO9780511543685
Hack S, Chow B (2001) Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 11(1):59–67
pubmed: 11322747 doi: 10.1089/104454601750143465
Lansky SB et al (1983) Psychological correlates of compliance. Am J Pediatr Hematol Oncol 5(1):87–92
pubmed: 6574716
Hoegy D et al (2019) Medication adherence in pediatric transplantation and assessment methods: a systematic review. Patient Prefer Adherence 13:705–719
pubmed: 31123396 pmcid: 6511245 doi: 10.2147/PPA.S200209
Gupta S, Bhatia S (2017) Optimizing medication adherence in children with cancer. Curr Opin Pediatr 29(1):41–45
pubmed: 27798425 pmcid: 7745131 doi: 10.1097/MOP.0000000000000434
Elhenawy YI et al (2022) Adherence to insulin therapy among children with type 1 diabetes: reliability and validity of the arabic version of the 4-item morisky medication adherence scale. Patient Prefer Adherence 16:1415–1421
pubmed: 35698632 pmcid: 9188330 doi: 10.2147/PPA.S341061
Schwartz DD et al (2010) Early risk factors for nonadherence in pediatric type 1 diabetes: a review of the recent literature. Curr Diabetes Rev 6(3):167–183
pubmed: 20380630 doi: 10.2174/157339910791162952
Shah R et al (2020) Adherence to multiple medications in the TODAY (treatment options for type 2 diabetes in adolescents and youth) cohort: effect of additional medications on adherence to primary diabetes medication. J Pediatr Endocrinol Metab 33(2):191–198
pubmed: 31809265 pmcid: 8201598 doi: 10.1515/jpem-2019-0315
Capoccia K, Odegard PS, Letassy N (2016) Medication adherence with diabetes medication: a systematic review of the literature. Diabetes Educ 42(1):34–71
pubmed: 26637240 doi: 10.1177/0145721715619038
Currie CJ et al (2013) The impact of treatment non-compliance on mortality in people with type 1 diabetes. J Diabetes Complications 27(3):219–223
pubmed: 23157988 doi: 10.1016/j.jdiacomp.2012.10.006
Borus JS, Laffel L (2010) Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr 22(4):405–411
pubmed: 20489639 pmcid: 3159529 doi: 10.1097/MOP.0b013e32833a46a7
Wicker E, Cole JW (2021) Sudden Unexpected Death in Epilepsy (SUDEP): a review of risk factors and possible interventions in children. J Pediatr Pharmacol Ther 26(6):556–564
pubmed: 34421404 pmcid: 8372858
Sveinsson O et al (2020) Pharmacologic treatment and SUDEP risk: a nationwide, population-based, case-control study. Neurology 95(18):e2509–e2518
pubmed: 32967928 pmcid: 7682832 doi: 10.1212/WNL.0000000000010874
Desai M, Oppenheimer JJ (2011) Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep 11(6):454–464
pubmed: 21968618 doi: 10.1007/s11882-011-0227-2
Kaplan A, Price D (2020) Treatment adherence in adolescents with asthma. J Asthma Allergy 13:39–49
pubmed: 32021311 pmcid: 6969681 doi: 10.2147/JAA.S233268
Herrera AM, Fitzgerald DA (2018) Question 1: why do children still die from asthma? Paediatr Respir Rev 27:40–43
pubmed: 29576240
Matthijssen AM et al (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry 176(9):754–762
pubmed: 31109200 doi: 10.1176/appi.ajp.2019.18111296
Lam WY, Fresco P (2015) Medication adherence measures: an overview. Biomed Res Int 2015:217047
pubmed: 26539470 pmcid: 4619779 doi: 10.1155/2015/217047
Parkin R, Nicholas FM, Hayden JC (2022) A systematic review of interventions to enhance adherence and persistence with ADHD pharmacotherapy. J Psychiatr Res 152:201–218
pubmed: 35753240 doi: 10.1016/j.jpsychires.2022.05.044

Auteurs

Maite Ferrin (M)

Child and Adolescent Mental Health Service, Barnet Enfield and Haringey NHS Trust, London, UK. maite.ferrin@nhs.net.
ReCognition Health, London, UK. maite.ferrin@nhs.net.

Alexander Häge (A)

Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

James Swanson (J)

Department of Pediatrics, University of California, Irvine, CA, USA.

Kirstie H T W Wong (KHTW)

Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.
Research Department of Practice and Policy, UCL School of Pharmacy, Mezzanine Floor, BMA House, Tavistock Square, London, WC1H 9JP, UK.

Ralf W Dittmann (RW)

Paediatric Psychopharmacology, Dept of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Heidelberg, Germany.

Tobias Banaschewski (T)

Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

David Coghill (D)

Departments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Murdoch Children's Research Institute, Melbourne, Australia.

Paramala J Santosh (PJ)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London, UK.

Marcel Romanos (M)

Department of Child and Adolescent Psychiatry, Center of Mental Health, University Hospital Wuerzburg, Würzburg, Germany.

Emily Simonoff (E)

Institute of Psychiatry, Psychology and Neuroscience and Maudsley NIHR Biomedical Research Centre, King's College London, London, UK.

Jan K Buitelaar (JK)

Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, The Netherlands.

Classifications MeSH